The Oncological Outcome of HIFU for the Treatment of Localized Prostate Cancer


  • Francesco Ziglioli Department of Urology, University-Hospital of Parma, Parma, Italy
  • Umberto Maestroni Department of Urology, University-Hospital of Parma, Parma, Italy



HIFU, high-intensity focused ultrasound, thermal ablation, prostate cancer, minimally-invasive procedures.


 Introduction: Prostate cancer is considered one of the most important health problems. Due to the increased number of diagnosed patients and the inability to distinguish aggressive tumors, minimally-invasive procedures have become increasingly interesting. High-intensity focused ultrasound (HIFU) is an alternative option to radical surgery to treat prostate cancer. To date, however, no data are available on the efficacy of this technique in comparison to standard treatment.

Methods and Results: We reviewed the literature to concentrate on the oncological outcome of HIFU treatment of prostate cancer with the following key words: hifu, high intensity focused ultrasound, ultrasonic therapy, transrectal hifu, prostate ablation. MedLine and Embase via Ovid database were searched. Selection criteria were: English language, articles published between 2006 and 2013, case series including more than 150 participants and reported data on oncological outcome. Thirteen uncontrolled studies were identified. No randomized controlled trials (RCT) were found in the literature comparing HIFU to other routine approaches to prostate cancer treatment.

Conclusion: HIFU seems to be a promising minimally-invasive treatment for low- and intermediate-risk prostate cancer, especially for patients who are unfit for radical surgery. Prospective studies with longer follow-up periods and RCT are required to properly assess the benefits of HIFU and to compare this treatment with standard treatment.


Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TL, et al. Mortality results from a randomized prostate cancer screening trial. N Engl J Med 2009; 360: 1310-9.

Shröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.

Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol 2008; 179: 2207-10.

Lynn JG, Zwermer RL, Chick AJ, Miller AE. A new method for the generation and use of focused ultrasound in experimental biology. J Gen Physiol 1942; 26: 179-93.

Lynn JG, Zwemer RL, Chick AJ. The biological application of focused ultrasound waves. Science 1942; 96: 119-20.

Fry WJ, Barnard JW, Fry FJ, Krumins RF, Brennan JF. Ultrasonically produced localized selective lesions in the central nervous system. Am J Phys Med 1955; 34: 413-23.

Barnett SB, Ter Harr GR, Ziskin MC, Nyborg WL, Maeda K, Bang J. Current status of research on biophysical effect of ultrasound. Ultrasound Med Biol 1994; 20: 205-18.

Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intesity focused ultrasound on prostate cancer in vivo. Cancer Res 1995; 55: 3346-51.

Kennedy JR, Ter Jaar GR, Cranston D. High intensity focused ultrasound: surgery of the future? Br J Radiol 2003; 76: 590-599.

Kim Y, Rhim H, Choi MJ, Lim HK, Choi D. High-intensity focused ultrasound therapy: an overview for radiologists. Korean J Radiol 2008; 9: 291-302.

Foster RS, Bihrle R, Sanghvi NT, Fry FJ, Donohue JP. High-intensity focused ultrasound in the treatment of prostatic disease. Eur Urol 1993; 23 (S1): 29-33.

Ter Haar G, Coussios C. High-intensity focused ultrasound: physical principles and devices. Int J Hyperthermia 2007; 23: 89-104.

Madersbacher S, Kratzik C, Marberger M. Prostatic tissue ablation by transrectal high intensity focused ultrasound: histological impact and clinical application. Ultrasonic Sonochemistry 1997; 4: 175-9.

Vaezy S, Andrew M, Kaczkowski P, Krum L. Image-guided acoustic therapy. Annu Rev Biomed Eng 2001; 3: 375-90.

Coleman JA, Scardino PT. Targeted prostate cancer ablation: energy options. Curr Opin Urol 2013; 23: 123-8.

Wenne JW, Preusser T, Günther M. High-intensity focused ultrasound: Principles, therapy, guidance, simulations and applications. Z Med Phys 2012; 22: 311-22.

Crouzet S, Murat FJ, Pasticier G, Cassier P, Chapelon JY, Gelet A. High-intensity focused ultrasound (HIFU) for prostate cancer: current clinical status, outcome and future perspectives. Int J Hyperthermia 2010; 26: 796-803.

Beerlage HP, van Leenders GJ, Oosterhof GO, Witjes JA, Ruijter ET, van der Kaa CA, et al. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy. Results of a prospective study. Prostate 1999; 39: 41-6.<41::AID-PROS7>3.0.CO;2-5

Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: Surgery of the future? Br J Radiol 2003; 76: 590-9.

Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N. Focal therapy of prostate cancer: energy and procedures. Urol Oncol 2013; 31: 155-167.

Susani M, Madersbacher S, Kratzik C, Vingers L, Margerger M. Morphology of tissue destruction induced by focused ultrasound. Eur Urol 1993; 23(Suppl. 1): 34-8.

Stride EP, Coussios CC. Cavitation and contrast: the use of bubbles in ultrasound images and therapy. Proc Inst Mech Engl 2010; 224: 171-91.

Chen H, Li X, Wang S. High-speed observation of cavitation bubble clouds near a tissue boundary in high-intensity focused ultrasound fields. Ultrasonics 2009; 49: 289-92.

Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T, et al. Five years experience of transrectal high-intensity ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006; 13: 228-33.

Rouviere O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001; 40: 265-74.

Ganzer R, Fritsche HM, Brandtner A, Bründl J, Coch D, Wieland WF, et al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 2013; 112: 322-9.

Chaussy C, Thüroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003; 4: 248-242.

Thüroff S, Chaussy C. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years. J Urol 2013; 190: 702-10.

Pfeiffer D, Berger J, Gross AJ. Single application of high-intensity focused ultrasound as first line therapy for clinically localized prostate cancer: 5-year outcomes. BJU Int 2012; 110: 1702-7.

Pinthus JH, Farrokyar F, Hassouna MM, Woods E, Whelan K, Shayegan B, et al. Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology. BJU Int 2012; 110: 1142-8.

Poissonier L, Chapelon JY, Rouvière O, Couvier L, Bouvier R, Martin X. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007; 51: 381-387.

Blana A, Robertson CN, Brown SC, Chaussy C, Crouzet S, Gelet A, et al. Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-registry. Prostate Cancer Prostatic Dis 2012; 15: 256-9.

Crouzet S, Chapelon JY, Rouvière O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol 2013. Article in press.

Uchida T, Shoji S, Nakano M, Hongo S, Masahiro N, Murota A, et al. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int J Urol 2009; 16: 881-6.

Sumitomo M, Hayashi M, Watanabe T, Tsugawa M, Noma H, Yamaguchi A, et al. Efficacy of short-term androgen depriva-tion with high-intensity scuse ultrasound in the treatment of prostate cancer in Japan. Urol 2008; 72: 1335-40.

Mearini L, D’urso L, Collura D, Zucchi A, Costantini E, Formiconi A, et al. Visually directed transrectal High Intensity Focused Ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 2009; 181: 105-112.

Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, et al. High-intensity focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 2009; 101: 19-26.

Murat FJ, Poissonier L, Rabilloud M, Belot A, Bouvier R, Rouvière O, et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 2009; 55: 640-649.

Hedenreich A, Bellmint J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU Guidelines on prostate cancer. Part 1: Screening, diagnosis and treatment of clinically localized disease. Eur Urol 2011; 59: 61-71.

Warmuth M, Johansson T, Mad P. Systematic review of efficacy and safety of high intensity focused ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol 2010; 58: 803-15.

Rebillard X, Soulié M, Chartier-Kastler E, Davin JL, Mignard JP, Moreau JL, et al. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 2008; 101: 1205-13.

British Uro-oncology Group, British Association of Urological Surgeons, Section of Oncology, British Prostate Group. MDT (multidisciplinary team) guidance for managing prostate cancer. Second edition. British Association of Urological Surgeons. Website BAUS/publications/mdt-prostate.

Guidelines on prostate cancer: diagnosis, staging and therapy [in Italian]. Associazione Urologi Italiani (Association of Italian Urologists). Website documenti-iniziative/linee-guida.

Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-974.

Blana A, Brown SC, Chaussy C, et al. High-intensity focused ultrasound for prostate cancer: comparative definition of biochemical failure. BJU Int 2009: 104: 1058-62.

D’Amico AV, Whittington R, Malkowicz SB, Shultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.




How to Cite

Francesco Ziglioli, & Umberto Maestroni. (2014). The Oncological Outcome of HIFU for the Treatment of Localized Prostate Cancer. Journal of Cancer Research Updates, 3(1),  67–72.